Chemicals · NSE: SUDEEPPHRM
Sudeep Pharma
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 29 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹13,212Cr
- P/E
- 69.9×
- 1Y return
- —
- From 52W high
- −15.1%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 197 | 163 | +20.9% | 158 | +24.3% |
| EBITDA | 73 | 55 | +32.1% | 55 | +33.4% |
| EBITDA margin | 37.2% | 34.1% | +313 bps | 34.7% | +254 bps |
| PBTProfit before tax | 71 | 60 | +19.3% | 54 | +30.8% |
| Net profit | 52 | 46 | +13.2% | 41 | +27.8% |
| EPS (₹) | 4.59 | 4.20 | +9.3% | 3.59 | +27.9% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
170 to 180 working capital days is this year's target
Ketan Vyas · Chief Financial Officer · p. 19
170 to 180 working capital days is this year's target
“As we said that about 170-odd days, 170, 180 days is our -- this year's target.”
Specialty Ingredients: Specialty Ingredients expected to show positive growth in Q3 and Q4
Shanil Bhayani · Whole · Q&A · p. 8
Specialty Ingredients: Specialty Ingredients expected to show positive growth in Q3 and Q4
“So we still remain comfortably confident that Q3, Q4, we should see positive growth contribution from specialty.”
Specialty Ingredients: Specialty Ingredients outlook does not assume a Fortified Rice restart
Shanil Bhayani · Whole · p. 4
Specialty Ingredients: Specialty Ingredients outlook does not assume a Fortified Rice restart
“Importantly, this expectation is based on customer contracts and new business alone and does not assume a restart of the Fortified Rice program.”
Pharma Food Nutrition: Commercial supplies from Nandesari greenfield expected to begin in H2 FY27
Shanil Bhayani · Whole · p. 5
Pharma Food Nutrition: Commercial supplies from Nandesari greenfield expected to begin in H2 FY27
“Customer qualifications are underway, and we expect commercial supplies to begin in H2 FY27 with utilization building as these qualifications convert into orders.”
ROCE expected to improve as projects start and scale up
Ketan Vyas · Chief Financial Officer · p. 7
ROCE expected to improve as projects start and scale up
“As this project commenced operations and scale up, we expect ROCE to improve.”
More figures from the call
“You can expect some growth, 10%, 15% utilization from this site in '28.”
“maybe from Q4 and then Q1 onwards is when you will start to see, I would say, a much larger 10%, 15%, 20% contribution from this category once we are able to start producing this at the new greenfield in Nandesari.”
“So we can assume 6 months, basically half year of FY28 to have commercial supplies and generate revenue for SAM.”
“During the quarter, the facility received FDA approval, marking a significant milestone. With annual capacity of 51,000 tons, it provides substantial headroom across our existing PFN portfolio and newer product categories, including glycinates, gluconates, citrates and phosphates.”
In short
- 01Q2 FY27 revenue was INR196 crores, up 21% year-on-year; EBITDA was INR73 crores, up 32%.
- 02Pharma Food Nutrition revenue grew 57% to INR142 crores, with segment EBITDA margin near 41%.
- 03Specialty Ingredients revenue fell 25% year-on-year as the Fortified Rice program paused; growth expected back in Q3 and Q4.
- 04Nandesari greenfield (51,000 tons a year) received FDA approval; supplies to begin in H2 FY27, 15-20% utilisation targeted in FY28.
- 05Magnesium bisglycinate seen as an INR100 crore-plus product in 2 to 3 years.
- 06Dahej battery materials Phase 1 (25,000 tons) on track for April 2027; binding offtake contracts targeted in Q4.
- 07Management aims to sustain current margin levels; NSS targets about 30% EBITDA margin in FY28.
- 08Working capital target of 170 to 180 days (ex-battery) for this year; net debt INR72.5 crores.
Capex
FY27 capex so far about INR77 crores, mainly Dahej battery project and greenfield
Ketan Vyas · Chief Financial Officer · p. 7
FY27 capex so far about INR77 crores, mainly Dahej battery project and greenfield
“Capital expenditure in FY27 was about INR77 crores, mainly towards the Battery Materials project at Dahej and the completion of the greenfield facility.”
Battery Materials: Battery investment pace tied to firm customer commitments
Shanil Bhayani · Whole · p. 5
Battery Materials: Battery investment pace tied to firm customer commitments
“The pace of investment will remain aligned with firm customer commitments and progress in the initial phase.”
Pharma Food Nutrition: Some capex needed to shift more Nandesari capacity to bisglycinates
Shanil Bhayani · Whole · Q&A · p. 11
Pharma Food Nutrition: Some capex needed to shift more Nandesari capacity to bisglycinates
“There would have to be certain capex -- not significant, but certain capex that would have to be made if we wanted to allocate more capacity to bisglycinates.”
Battery Materials: Phase 2 and Phase 3 expansion need not wait for Phase 1 commissioning
Shanil Bhayani · Whole · Q&A · p. 16
Battery Materials: Phase 2 and Phase 3 expansion need not wait for Phase 1 commissioning
“And then we would base our scale-up or our Phase 2 expansion, Phase 3 expansion based on those plans. It doesn't necessarily -- we don't have to wait until our Phase 1 is commissioned.”
Battery Materials: Back-end engineering design for later phases already under way
Shanil Bhayani · Whole · Q&A · p. 16
Battery Materials: Back-end engineering design for later phases already under way
“And a lot of back-end engineering design work is something that we are already doing to kind of curtail the time to market.”
Capacity
Battery Materials: Planned battery materials expansion towards 200,000 tons a year
Shanil Bhayani · Whole · p. 5
Battery Materials: Planned battery materials expansion towards 200,000 tons a year
“In parallel, customer discussions for the next phase are progressing faster than expected, giving us increasing confidence in our planned expansion towards 200,000 tons of annual capacity.”
Pharma Food Nutrition: 40% of Nandesari capacity for other products; 70-80% of that to bisglycinate
Shanil Bhayani · Whole · Q&A · p. 11
Pharma Food Nutrition: 40% of Nandesari capacity for other products; 70-80% of that to bisglycinate
“So currently, 40% of our capacity is allocated to other products, which includes bisglycinate, gluconate and citrate. The capacity is fairly fungible. Today, we expect out of that 40%, majority -- at least closer to 70%, 80% will go to bisglycinate”
Pharma Food Nutrition: Existing Nandesari PFN site running closer to 80% utilisation
Shanil Bhayani · Whole · Q&A · p. 17
Pharma Food Nutrition: Existing Nandesari PFN site running closer to 80% utilisation
“Maybe we would have stressed it slightly higher, so it may be closer to 80% utilization.”
Pharma Food Nutrition: Customers take 6 to 12 months to approve the new PFN facility
Shanil Bhayani · Whole · Q&A · p. 13
Pharma Food Nutrition: Customers take 6 to 12 months to approve the new PFN facility
“Typically, it will -- a lot of -- it takes 6 to 12 months, as I mentioned before, for customers to approve this facility. Some approvals are already in place.”
Pharma Food Nutrition: Current facilities operating close to optimum utilisation
Shanil Bhayani · Whole · p. 4
Pharma Food Nutrition: Current facilities operating close to optimum utilisation
“With our current facilities operating close to optimum utilization, additional capacity is an important next step.”
Order book
Battery Materials: Update on firm binding battery offtake contracts expected in Q4
1,00,000tonsShanil Bhayani · Whole · p. 5
Battery Materials: Update on firm binding battery offtake contracts expected in Q4
1,00,000tons“We see strong demand to support the first 100,000 ton annual capacity, and we expect to provide a more concrete update on firm binding offtake contracts in Q4.”
Battery Materials: Binding battery offtake volumes to be shared in next 2 months or next call
Shanil Bhayani · Whole · Q&A · p. 13
Battery Materials: Binding battery offtake volumes to be shared in next 2 months or next call
“In the next 2 months or maybe in our next call, we would be at a point where we can very openly share with everyone how our binding -- for what volume our binding agreements are secured.”
Battery Materials: Binding battery commitments targeted in Q4, before April 2027 commissioning
Shanil Bhayani · Whole · Q&A · p. 16
Battery Materials: Binding battery commitments targeted in Q4, before April 2027 commissioning
“So our target today is to be able to sign binding commitments, as I mentioned, in Q4. So that would still largely be before we commission our Phase 1 in April '27.”
Segments
Specialty Ingredients: Specialty Ingredients revenue INR54 crores, up 9% sequentially, down 25% year-on-year
Shanil Bhayani · Whole · p. 3
Specialty Ingredients: Specialty Ingredients revenue INR54 crores, up 9% sequentially, down 25% year-on-year
“Revenue stood at INR54 crores, up 9% sequentially, although 25% lower year-on-year.”
Pharma Food Nutrition: PFN revenue grew 57% to INR142 crores, about 72% of consolidated revenue
Shanil Bhayani · Whole · p. 4
Pharma Food Nutrition: PFN revenue grew 57% to INR142 crores, about 72% of consolidated revenue
“Revenue grew 57% year-on-year to INR142 crores, contributing approximately 72% of consolidated revenue.”
Pharma Food Nutrition: Bisglycinate Q1 sales exceeded all of FY26; momentum continued in Q2
Shanil Bhayani · Whole · p. 5
Pharma Food Nutrition: Bisglycinate Q1 sales exceeded all of FY26; momentum continued in Q2
“As we mentioned on the previous call, Q1 sales had already exceeded sales for the whole of FY26 and the momentum continued in Q2.”
Specialty Ingredients: Non-rice premix demand in Q3, Q4 expected to almost entirely offset rice loss
Shanil Bhayani · Whole · Q&A · p. 8
Specialty Ingredients: Non-rice premix demand in Q3, Q4 expected to almost entirely offset rice loss
“we have very good visibility for non-fortified rice demand for specifically the premix business for Q3 and Q4, which will largely offset or I would say, almost entirely offset the loss of revenue due to Fortified rice but also additionally contribute to growing this category.”
Pharma Food Nutrition: No contribution yet from new Nandesari site in PFN growth
Shanil Bhayani · Whole · Q&A · p. 8
Pharma Food Nutrition: No contribution yet from new Nandesari site in PFN growth
“So, as you rightly mentioned, the FDA approval for the greenfield only came last week. So there is 0 contribution from the new site.”
Demand
Specialty Ingredients: New approvals from large nutrition customers; revenue expected from Q3
Shanil Bhayani · Whole · p. 4
Specialty Ingredients: New approvals from large nutrition customers; revenue expected from Q3
“During Q2, we received approvals from large customers across infant nutrition, dietary supplements and human nutrition with commercial revenues expected to begin in Q3.”
Pharma Food Nutrition: Bisglycinate approvals: 8 or 9 in US, close to 30-35 globally
Shanil Bhayani · Whole · Q&A · p. 9
Pharma Food Nutrition: Bisglycinate approvals: 8 or 9 in US, close to 30-35 globally
“U.S. alone, I think we have, maybe 8 or 9 approvals. I would say globally, if I were to include India, Europe, I would say close to maybe 30, 35 approvals is what we have.”
Battery Materials: Battery capacity to focus on 5 to 7 large customers in Korea, Europe, US
Shanil Bhayani · Whole · Q&A · p. 10
Battery Materials: Battery capacity to focus on 5 to 7 large customers in Korea, Europe, US
“what we are largely focused on is how we can scale the partnership with, say, 5 or 7 customers, large customers -- the large Korean customers in Korea, Europe and the U.S. and allocating capacity to them.”
Pharma Food Nutrition: Global magnesium bisglycinate market close to $1 billion; US $400-450 million
Shanil Bhayani · Whole · Q&A · p. 10
Pharma Food Nutrition: Global magnesium bisglycinate market close to $1 billion; US $400-450 million
“globally, the opportunity for the magnesium bisglycinate ingredient is close to $1 billion. 40% to 45%, so roughly $400 million to $450 million is from the U.S. alone.”
Pharma Food Nutrition: Bisglycinate volume planned about 50% to large customers, 50% diversified
Shanil Bhayani · Whole · Q&A · p. 10
Pharma Food Nutrition: Bisglycinate volume planned about 50% to large customers, 50% diversified
“So I would say maybe 50% demand would come -- 50% of the volume would go to larger customers globally as well as in India. And then the remaining 50% would be kind of diversified with mid- to smaller companies.”
Margins and costs
Q2 EBITDA INR73 crores, up 32% year-on-year
Shanil Bhayani · Whole · p. 3
Q2 EBITDA INR73 crores, up 32% year-on-year
“EBITDA stood at INR73 crores, up 32% year-on-year.”
Pharma Food Nutrition: PFN segment EBITDA margin about 41% vs 33% a year ago
Shanil Bhayani · Whole · p. 4
Pharma Food Nutrition: PFN segment EBITDA margin about 41% vs 33% a year ago
“Segment EBITDA margin increased to approximately 41% from 33% a year ago, while segment EBITDA nearly doubled.”
Pharma Food Nutrition: Magnesium bisglycinate realisation more than 3x PFN portfolio average
Shanil Bhayani · Whole · p. 5
Pharma Food Nutrition: Magnesium bisglycinate realisation more than 3x PFN portfolio average
“It also supports a higher value product mix with average realization more than 3x the average of our PFN portfolio.”
Greenfield plant capitalised in Q2; its expenses now charged to P&L
Ketan Vyas · Chief Financial Officer · p. 6
Greenfield plant capitalised in Q2; its expenses now charged to P&L
“Our new greenfield plant is capitalized in the current quarter and put to use. With that being operative, expense related to plant are now getting charged to the P&L.”
Specialty Ingredients: Specialty margins depressed by low premix revenue and NSS drag
Shanil Bhayani · Whole · Q&A · p. 8
Specialty Ingredients: Specialty margins depressed by low premix revenue and NSS drag
“I think our premix, which was a large contributor, generated limited revenue, plus I would say that impact, along with the drag from NSS is what kind of depressed the margins in Specialty.”
Debt and working capital
H1 cash flow from operations INR43.5 crores, up INR26 crores
Ketan Vyas · Chief Financial Officer · p. 7
H1 cash flow from operations INR43.5 crores, up INR26 crores
“At the end of H1 FY27, at consol level, cash flow from operations was INR43.5 crores, up by INR26 crores on a year-on-year basis, driven by higher profitability and stable working capital.”
Net working capital days at 214 as of 30 September 2026
Ketan Vyas · Chief Financial Officer · p. 7
Net working capital days at 214 as of 30 September 2026
“We remain focused on the working capital discipline and net working capital days remained at 214 days as on 30th September 2026, similar to the level of March '26.”
Raw materials like purified phosphoric acid stocked due to geopolitical situation
Ketan Vyas · Chief Financial Officer · p. 7
Raw materials like purified phosphoric acid stocked due to geopolitical situation
“Considering the geopolitical situation, we strategically stocked the raw materials of -- key raw materials like purified phosphoric acid to ensure our finished good demands are met through enough supply of raw material.”
Net debt INR72.5 crores, net debt-to-equity about 0.07x
Ketan Vyas · Chief Financial Officer · p. 7
Net debt INR72.5 crores, net debt-to-equity about 0.07x
“Net debt was INR72.5 crores as of 30th September 2026 with net debt-to-equity ratio of about 0.07x compared with INR33.6 crores and 0.04x as of 31st March '26.”
Inventory built in Q1 supports business through October and November
Shanil Bhayani · Whole · Q&A · p. 11
Inventory built in Q1 supports business through October and November
“we basically built up a lot of inventory in Q1, which has catered the business in Q2 and will kind of also support the business in all of October, also November.”
Acquisitions and new business
Pharma Food Nutrition: Plan to launch dedicated brand MaxZobis for supplement customers
Shanil Bhayani · Whole · p. 5
Pharma Food Nutrition: Plan to launch dedicated brand MaxZobis for supplement customers
“We plan to introduce a dedicated brand, MaxZobis to strengthen the product visibility with supplement and nutrition customers.”
One-offs
PAT lagged EBITDA on lower other income and 27% tax rate vs about 21%
Ketan Vyas · Chief Financial Officer · p. 6
PAT lagged EBITDA on lower other income and 27% tax rate vs about 21%
“Year-on-year, PAT growth was lower than EBITDA growth, mainly because of other income, which was lower by INR6 crores against INR10.2 crores in Q2 FY26, and our effective tax rate was at 27% compared to about 21% last year.”
Risks
Selling and distribution cost about INR8 crores above normal in Q2, mainly freight
Shanil Bhayani · Whole · p. 3
Selling and distribution cost about INR8 crores above normal in Q2, mainly freight
“Our selling and distribution expenditure was approximately INR8 crores above the normal quarterly average, largely because of freight.”
Specialty Ingredients: No visibility on whether Fortified Rice program restarts this financial year
Shanil Bhayani · Whole · p. 4
Specialty Ingredients: No visibility on whether Fortified Rice program restarts this financial year
“That contribution was absent this quarter, and we currently do not have visibility on whether the program will restart during this financial year.”
Specialty Ingredients: Rice program was about 20% to 25% of Specialty Ingredients revenue
Shanil Bhayani · Whole · Q&A · p. 8
Specialty Ingredients: Rice program was about 20% to 25% of Specialty Ingredients revenue
“So broadly speaking, let's say, for the full year, the revenue contribution from the rice program was approximately, say, around 20% to 25% of our overall Specialty Ingredients revenue, right?”
Battery Materials: Other players in India and globally will produce battery-grade iron phosphate
Shanil Bhayani · Whole · Q&A · p. 14
Battery Materials: Other players in India and globally will produce battery-grade iron phosphate
“So let's say, if I were to tell you, iron phosphate 100%, there will be other players in India and globally who will produce battery-grade iron phosphate.”
Other
Q2 revenue from operations INR196 crores, up 21% year-on-year and 24% sequentially
Shanil Bhayani · Whole · p. 3
Q2 revenue from operations INR196 crores, up 21% year-on-year and 24% sequentially
“Revenue from operations reached INR196 crores, growing 21% year-on-year and 24% sequentially.”
Q2 PAT INR51 crores, up 11%, on higher tax rate and lower other income
Shanil Bhayani · Whole · p. 3
Q2 PAT INR51 crores, up 11%, on higher tax rate and lower other income
“PAT stood at INR51 crores, growing 11%, reflecting a higher effective blended tax rate together with lower other income.”
Exports about 65% of revenue; exports grew 24% year-on-year
Ketan Vyas · Chief Financial Officer · p. 7
Exports about 65% of revenue; exports grew 24% year-on-year
“By geography, export accounted for about 65% of revenue and domestic sales for about 35%. Exports grew 24% year-on-year.”
H1 FY27 revenue INR355 crores, up 23% year-on-year
Ketan Vyas · Chief Financial Officer · p. 7
H1 FY27 revenue INR355 crores, up 23% year-on-year
“Revenue from operations for H1 FY27 grew 23% year-on-year to INR355 crores compared with INR287.6 crores in H1 FY26.”
H1 FY27 PAT INR92.4 crores, up 18% year-on-year
Ketan Vyas · Chief Financial Officer · p. 7
H1 FY27 PAT INR92.4 crores, up 18% year-on-year
“PAT grew 18% year-on-year to INR92.4 crores compared with INR78 crores in H1 FY26.”
Sources
- Earnings call transcript, Q2 FY27 Filed 3 Nov 2026 · 21 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

